Clinical Trials Logo
  1. Home
  2. Severe Alcoholic Hepatitis
  3. NCT02808663

Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis — CALPRO-HAA  

Severe Alcoholic Hepatitis Clinical Trial

Official title:
Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis

Clinical Trial Summary

Severe alcoholic hepatitis, defined by a "Maddrey discriminant function" above 32, is associated with significant short-term mortality. In patients with liver disease, studies have shown alterations of intestinal bacterial flora and an increase in intestinal permeability leading to bacterial translocation across the intestinal barrier. The mechanism involved may be an activation of intestinal macrophages with a local release of cytokines like interleukin-8 (IL-8).

Calprotectin is a protein present in large amounts in the cytosol of neutrophils. Its presence in feces is related to neutrophil migration in intestinal lumen. Thus, fecal calprotectin may be used as a marker of intestinal inflammation. There is evidence that fecal calprotectin levels are increased in cirrhotic patients dependent on the severity of the disease. The predictive value of fecal calprotectin for the outcome of severe alcoholic hepatitis has never been evaluated.

The main objective of this study was to determine if the initial level of fecal calprotectin and its variation after 7 days had a predictive value for the outcome of severe alcoholic hepatitis. Secondary objectives were to determine if fecal calprotectin concentration was correlated with blood concentration of Lipopolysaccharide (LPS) binding protein and predictive of infections.

Clinical Trial Description

Severe alcoholic hepatitis, defined by a "Maddrey discriminant function" above 32, is associated with significant short-term mortality. In patients with liver disease, studies have shown alterations of intestinal bacterial flora and an increase in intestinal permeability leading to bacterial translocation across the intestinal barrier. The mechanism involved may be an activation of intestinal macrophages with a local release of cytokines like IL-8.

Calprotectin is a protein present in large amounts in the cytosol of neutrophils. Its presence in feces is related to neutrophil migration in intestinal lumen. Thus, fecal calprotectin may be used as a marker of intestinal inflammation. There is evidence that fecal calprotectin levels are increased in cirrhotic patients dependent on the severity of the disease. The predictive value of fecal calprotectin for the outcome of severe alcoholic hepatitis has never been evaluated.

The main objective of this study was to determine if the initial level of fecal calprotectin and its variation after 7 days had a predictive value for the outcome of severe alcoholic hepatitis. Secondary objectives were to determine if fecal calprotectin concentration was correlated with blood concentration of LPS binding protein and predictive of infections. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02808663
Study type Interventional
Source CHU de Reims
Contact
Status Completed
Phase N/A
Start date May 6, 2015
Completion date February 1, 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04106518 - Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Not yet recruiting NCT06155760 - Role of Extended Low Dose Prednisolone in Achieving Clinical and Biochemical Remission in Steroid Responsive Severe Alcoholic Hepatitis N/A
Completed NCT01820208 - Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis N/A
Withdrawn NCT03087968 - Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124 Early Phase 1
Not yet recruiting NCT02485106 - Rifaximin Use in Severe Alcoholic Hepatitis Phase 3
Recruiting NCT03827772 - Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis- Assessment of Impact on Prognosis and Short-term Outcome N/A
Completed NCT01801332 - Intensive Enteral Nutrition and Acute Alcoholic Hepatitis N/A
Recruiting NCT04103840 - Invasive Fungal Infections in Severe Alcohol-associated Hepatitis
Active, not recruiting NCT03091010 - A Comparison of Fecal Microbiota Transplantation and Steroid Therapy in Patients With Severe Alcoholic Hepatitis. N/A
Completed NCT02161653 - Metadoxine as a Therapy for Severe Alcoholic Hepatitis Phase 4